Expanded Access for ABI-009 in Patients With Advanced PEComa and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

TSC1 Clinical Trial

Official title:
Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients With Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients With a Malignancy With Relevant Genetic Mutations or mTOR Pathway Activation

Status Approved for marketing

Clinical Trial Summary

Expanded Access for an Intermediate-size Population for ABI-009 (Sirolimus Albumin-bound Nanoparticles for Injectable Suspension) in Patients with Advanced Perivascular Epithelioid Cell Tumors (PEComa) and Patients with a Malignancy with Relevant Genetic Mutations or mTOR Pathway Activation

Clinical Trial Description

Study Design

Related Conditions & MeSH terms

mTOR Pathway Abberation
PEComa, Malignant
Perivascular Epithelioid Cell Neoplasms
TSC1
TSC2

Clinical Trial Details

NCT number	NCT03817515
Study type	Expanded Access
Source	Aadi, LLC
Contact
Status	Approved for marketing
Phase

View Details

See also
	Status	Clinical Trial	Phase
	Completed	`NCT02201212` - Everolimus for Cancer With TSC1 or TSC2 Mutation	Phase 2
	Active, not recruiting	`NCT05103358` - Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1)	Phase 2